The Korean journal of internal medicine

  • 제32권3호
  • /
  • Pages.497-504
  • /
  • 2017
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study

  • Kim, Hae Jin (Department of Endocrinology and Metabolism, Ajou University School of Medicine) ;
  • Han, Seung Jin (Department of Endocrinology and Metabolism, Ajou University School of Medicine) ;
  • Kim, Dae Jung (Department of Endocrinology and Metabolism, Ajou University School of Medicine) ;
  • Jang, Hak Chul (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Lim, Soo (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Choi, Sung Hee (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Kim, Yong Hyun (Department of Internal Medicine, Daejin Medical Center, Bundang Jesaeng Hospital) ;
  • Shin, Dong Hyun (Department of Internal Medicine, Daejin Medical Center, Bundang Jesaeng Hospital) ;
  • Kim, Se Hwa (Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine) ;
  • Kim, Tae Ho (Department of Internal Medicine, Seoul Medical Center) ;
  • Ahn, Yu Bae (Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea) ;
  • Ko, Seung Hyun (Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea) ;
  • Kim, Nan Hee (Department of Internal Medicine, Korea University Ansan Hospital) ;
  • Seo, Ji A (Department of Internal Medicine, Korea University Ansan Hospital) ;
  • Kim, Ha Young (Department of Internal Medicine, Wonkwang University Sanbon Hospital) ;
  • Lee, Kwan Woo (Department of Endocrinology and Metabolism, Ajou University School of Medicine)
  • 투고 : 2015.12.17
  • 심사 : 2016.05.29
  • 발행 : 2017.05.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Oxidative stress plays an important role in the pathogenesis and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress. In this study, we compared the changes in oxidative stress markers after valsartan and amlodipine treatment in type 2 diabetic patients with hypertension and compared the changes in metabolic parameters. Methods: Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks. We measured serum nitrotyrosine levels as an oxidative stress marker. Metabolic parameters including serum glucose, insulin, lipid profile, and urine albumin and creatinine were also measured. Results: After 24 weeks of valsartan or amlodipine treatment, systolic and diastolic blood pressure decreased, with no significant difference between the groups. Both groups showed a decrease in serum nitrotyrosine ($7.74{\pm}7.30nmol/L$ vs. $3.95{\pm}4.07nmol/L$ in the valsartan group and $8.37{\pm}8.75nmol/L$ vs. $2.68{\pm}2.23nmol/L$ in the amlodipine group) with no significant difference between the groups. Other parameters including glucose, lipid profile, albumin-to-creatinine ratio, and homeostasis model assessment of insulin resistance showed no significant differences before and after treatment in either group. Conclusions: Valsartan and amlodipine reduced the oxidative stress marker in type 2 diabetic patients with hypertension.

키워드

참고문헌

  1. Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-2222. https://doi.org/10.1016/S0140-6736(10)60484-9
  2. Hu G, Jousilahti P, Tuomilehto J. Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J 2007;28:3059-3066. https://doi.org/10.1093/eurheartj/ehm501
  3. Hsueh WA, Wyne K. Renin-angiotensin-aldosterone system in diabetes and hypertension. J Clin Hypertens (Greenwich) 2011;13:224-237. https://doi.org/10.1111/j.1751-7176.2011.00449.x
  4. Araki E, Nishikawa T. Oxidative stress: a cause and therapeutic target of diabetic complications. J Diabetes Investig 2010;1:90-96. https://doi.org/10.1111/j.2040-1124.2010.00013.x
  5. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-1070. https://doi.org/10.1161/CIRCRESAHA.110.223545
  6. Dikalov SI, Ungvari Z. Role of mitochondrial oxidative stress in hypertension. Am J Physiol Heart Circ Physiol 2013;305:H1417-H1427. https://doi.org/10.1152/ajpheart.00089.2013
  7. Chabrashvili T, Kitiyakara C, Blau J, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003;285:R117-R124. https://doi.org/10.1152/ajpregu.00476.2002
  8. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001;103:799-805. https://doi.org/10.1161/01.CIR.103.6.799
  9. Fliser D, Buchholz K, Haller H; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103-1107. https://doi.org/10.1161/01.CIR.0000140265.21608.8E
  10. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis 2002;165:191-199. https://doi.org/10.1016/S0021-9150(01)00729-8
  11. Aksnes TA, Skarn SN, Kjeldsen SE. T reatment of hypertension in diabetes: what is the best therapeutic option? Expert Rev Cardiovasc Ther 2012;10:727-734. https://doi.org/10.1586/erc.12.59
  12. Zhou MS, Schulman IH, Jaimes EA, Raij L. Thiazide diuretics, endothelial function, and vascular oxidative stress. J Hypertens 2008;26:494-500. https://doi.org/10.1097/HJH.0b013e3282f3e39d
  13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
  14. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 2008;5:338-349. https://doi.org/10.1038/ncpcardio1211
  15. Ho E, Karimi Galougahi K, Liu CC, Bhindi R, Figtree GA. Biological markers of oxidative stress: applications to cardiovascular research and practice. Redox Biol 2013;1:483-491. https://doi.org/10.1016/j.redox.2013.07.006
  16. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006;52:601-623. https://doi.org/10.1373/clinchem.2005.061408
  17. Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002;22:1257-1266. https://doi.org/10.1161/01.ATV.0000021412.56621.A2
  18. Shimada K, Murayama T, Yokode M, Kita T, Fujita M, Kishimoto C. Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production. Nutr Metab Cardiovasc Dis 2011;21:672-678. https://doi.org/10.1016/j.numecd.2009.12.016
  19. American Diabetes Association. 8. Cardiovascular disease and risk management. Diabetes Care 2016;39 Suppl 1:S60-S71. https://doi.org/10.2337/dc16-S011
  20. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 2003;26:691-697. https://doi.org/10.1291/hypres.26.691
  21. Yung LM, Wong WT, Tian XY, et al. Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats. PLoS One 2011;6:e17437. https://doi.org/10.1371/journal.pone.0017437
  22. Wu B, Lin R, Dai R, Chen C, Wu H, Hong M. Valsartan attenuates oxidative stress and NF-${\kappa}B$ activation and reduces myocardial apoptosis after ischemia and reperfusion. Eur J Pharmacol 2013;705:140-147. https://doi.org/10.1016/j.ejphar.2013.02.036
  23. Zhou G, Cheung AK, Liu X, Huang Y. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation. Clin Sci (Lond) 2014;126:707-720. https://doi.org/10.1042/CS20130223
  24. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003;23:2155-2163. https://doi.org/10.1161/01.ATV.0000097770.66965.2A
  25. Park CG. Is amlodipine more cardioprotective than other antihypertensive drug classes? Korean J Intern Med 2014;29:301-304. https://doi.org/10.3904/kjim.2014.29.3.301
  26. Takebayashi K, Naruse R, Aso Y, Inukai T. The effect of amlodipine on oxidative stress in patients with type 2 diabetes. SRX Med 2010;2010:326840.
  27. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031. https://doi.org/10.1016/S0140-6736(04)16451-9
  28. Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens 2014;8:340-349. https://doi.org/10.1016/j.jash.2014.02.004
  29. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004;43:2116-2123. https://doi.org/10.1016/j.jacc.2003.12.051
  30. Naya M, Tsukamoto T, Morita K, et al. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007;50:1144-1149. https://doi.org/10.1016/j.jacc.2007.06.013
  31. Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens 2008;30:267-276. https://doi.org/10.1080/10641960802071000
  32. Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int 2006;70:2109-2115. https://doi.org/10.1038/sj.ki.5001983
  33. Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010;56:77-85. https://doi.org/10.1016/j.jacc.2010.02.046

피인용 문헌

  1. Oxidative stress: link between hypertension and diabetes vol.32, pp.3, 2017, https://doi.org/10.3904/kjim.2017.153
  2. In vivo Assessment of Combined Effects of Glibenclamide and Losartan in Diabetic Rats vol.28, pp.2, 2017, https://doi.org/10.1159/000496104
  3. Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation vol.20, pp.14, 2017, https://doi.org/10.3390/ijms20143458
  4. Blockade of Renin Angiotensin System Ameliorates the Cardiac Arrhythmias and Sympathetic Neural Remodeling in Hearts of Type 2 DM Rat Model vol.20, pp.3, 2017, https://doi.org/10.2174/1871530319666190809150921
  5. Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature vol.37, pp.8, 2017, https://doi.org/10.1007/s12325-020-01417-8
  6. Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature vol.37, pp.8, 2017, https://doi.org/10.1007/s12325-020-01417-8
  7. The Effects of Valsartan on Cardiac Function and Pro-Oxidative Parameters in the Streptozotocin-Induced Diabetic Rat Heart vol.21, pp.3, 2017, https://doi.org/10.2478/sjecr-2018-0049
  8. Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension vol.6, pp.None, 2017, https://doi.org/10.1038/s41421-020-00235-0
  9. Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and In Vitro Study vol.2021, pp.None, 2017, https://doi.org/10.1155/2021/5575545
  10. Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform vol.26, pp.7, 2017, https://doi.org/10.3390/molecules26071912
  11. Effect of biscuits formulated from acha-sandpaper leaf composite flour on fasting blood glucose, blood pressure, and activities of key enzymes linked to diabetes and hypertension in streptozotocin/ https://doi.org/10.1111/jfbc.13843
  12. Protective effect of valsartan against doxorubicin‐induced cardiotoxicity: Histopathology and metabolomics in vivo study vol.35, pp.9, 2021, https://doi.org/10.1002/jbt.22842